What do systematic reviews say?

GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone

It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes pregnancy compared with chemotherapy alone (very low certainty).

• Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure… 2019 · Cochrane Headline outcomes only
  RR 3 [0.13, 70.3]
  1 study · 50 participants
  Very low

GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone

• Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone

• Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone

It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes menstruation recovery or maintenance: compared with chemotherapy alone (very low certainty).

• Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure… 2019 · Cochrane Headline outcomes only
  RR 1 [0.76, 1.32]
  1 study · 50 participants
  Very low
• Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure… 2019 · Cochrane Headline outcomes only
  RR 0.93 [0.56, 1.55]
  1 study · 50 participants
  Very low

GnRH agonists vs HCG

GnRH agonist probably leads to lower live birth compared with HCG (moderate certainty).

• Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology 2014 · Cochrane Headline outcomes only
  OR 0.47 [0.31, 0.7]
  5 studies · 532 participants
  Moderate

GnRH agonists vs HCG

GnRH agonist probably leads to lower OHSS (mild, moderate or severe): overall risk compared with HCG (moderate certainty).

• Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology 2014 · Cochrane Headline outcomes only
  OR 0.15 [0.05, 0.47]
  8 studies · 989 participants
  Moderate

GnRH agonists vs HCG

GnRH agonist probably leads to lower OHSS (moderate or severe): overall risk compared with HCG (moderate certainty).

• Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology 2014 · Cochrane Headline outcomes only
  OR 0.21 [0.07, 0.66]
  8 studies · 989 participants
  Moderate

GnRH agonists vs HCG

GnRH agonist probably leads to lower OHSS (mild, moderate or severe) in women at high risk of OHSS compared with HCG (moderate certainty).

• Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology 2014 · Cochrane Headline outcomes only
  OR 0.06 [0.01, 0.34]
  3 studies · 212 participants
  Moderate

GnRH agonists vs HCG

GnRH agonist may leads to lower ongoing pregnancy compared with HCG (low certainty).

• Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology 2014 · Cochrane Headline outcomes only
  OR 0.7 [0.54, 0.91]
  11 studies · 1198 participants
  Low

GnRH agonists vs HCG

GnRH agonist probably leads to higher miscarriage compared with HCG (moderate certainty).

• Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology 2014 · Cochrane Headline outcomes only
  OR 1.74 [1.1, 2.75]
  11 studies · 1198 participants
  Moderate